Information Provided By: 
Fly News Breaks for September 20, 2017
ALNY, BIIB, IONS
Sep 20, 2017 | 10:06 EDT
Evercore ISI Joshua Schimmer said he wouldn't be surprised to see Ionis (IONS) shares fall 5%-10% after competitor Alnylam (ALNY) reported positive results from the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. However, he believes the Ionis story continues to be about the Spinraza launch in SMA with partner Biogen (BIIB) and its Huntington's data later this year. He keeps an Outperform rating and $65 price target on Ionis shares, which are down nearly 9% in early trading to $53.92.
News For IONS;BIIB;ALNY From the Last 2 Days
